APPLICATIONS PUBLISHED 26 JANUARY 2005

Published: 3-Jan-2006

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

  • Use of haem oxygenase-1 and products of haem degradation
    Beth Israel Deaconess Medical Centre 1499186*

  • Immunostimulatory G,U-containing oligoribonucleotides
    Coley Pharmaceutical 1499187*

  • Method of reducing calcified arterial plaque build-up and cellular malfunction and for balancing ionic calcium
    Gusty Winds Corp 1499189*

  • Methods for treating liver disease and liver damage with growth hormone and FOXM1B
    The Board of Trustees of the University of Illinois 1496190*

  • Regulated attentuation of live vaccines to enhance cross protective immunogenicity
    Washington University in St Louis 1499191*

  • Biologically active compounds for the modification of bodily odours
    Max-Planck-Gesellshaft zur Foerderung des Wissenschaften 1499284*

  • Volume efficient controlled release dosage form
    Alza Corp 1499289*

  • Method and dosage forms for controlled delivery of oxycodone
    Alza Corp 1499291*

  • In vivo imaging of apoptosis
    The General Hospital Corp 1499292*

  • Topical application of alpha-DFMO and anti-inflammatory drug for the treatment of actinic keratoses
    Topical Technologies 1499293*

  • Transport system in biological systems
    Biotesys 1499294*

  • Sustained release metoprolol formulations
    Penwest Pharmaceuticals 1499295*

  • Formulation of fine particles using liquefied or dense gases
    Eiffel Technologies 1499297*

  • Pharmaceutical formulation comprising atorvastatin calcium
    Lek Pharmaceutical and Chemical 1499297*

  • Oral administration form for difficulty soluble basic active ingredients which are applied orally
    Boehringer Ingelheim Pharma 1499298*

  • Microparticle pharmaceutical compsns for intratumoural delivery
    Teva Pharmaceutical Industries; West Pharmaceutical Services Drug Delivery & Clinical Research Centre 1499299*

  • Pharmaceutical formulations with improved bioavailability
    Shire Laboratories; Shojaei, Amir; Flanner, Henry; Ibrahim, Scott 1499300*

  • You may also like